Caroline E. Ridgway

2.2k total citations · 1 hit paper
12 papers, 1.4k citations indexed

About

Caroline E. Ridgway is a scholar working on Infectious Diseases, Virology and Oncology. According to data from OpenAlex, Caroline E. Ridgway has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Virology and 3 papers in Oncology. Recurrent topics in Caroline E. Ridgway's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (3 papers). Caroline E. Ridgway is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (3 papers). Caroline E. Ridgway collaborates with scholars based in United Kingdom, United States and Belgium. Caroline E. Ridgway's co-authors include Sylvie Abel, Elna van der Ryst, Gary J. Muirhead, Deborah Russell, James Goodrich, Bonaventura Clotet, Michael W. Dunne, Steve Felstead, Nathan Clumeck and Jeffrey P. Nadler and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Caroline E. Ridgway

12 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers

Caroline E. Ridgway

VIROL

ID

IMMUN

EPIDE

MB

Margalida Rotger Switzerland

Alonso Heredia United States

Gabriela Bleiber Switzerland

James J. Kohler United States

Stephen Becker United States

Patrick Dorr United Kingdom

Andrew Mulato United States

Scott C. Brun United States

Gabriel Birkuš United States

Patricia Barditch‐Crovo United States

Margalida Rotger Switzerland

Caroline E. Ridgway

849 ×0.8

VIROL

1.1k ×1.2

ID

168 ×0.7

IMMUN

266 ×1.1

EPIDE

245 ×1.4

MB

Citations per year, relative to Caroline E. Ridgway Caroline E. Ridgway (= 1×) peers Margalida Rotger

Countries citing papers authored by Caroline E. Ridgway

Since Specialization

Citations

This map shows the geographic impact of Caroline E. Ridgway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline E. Ridgway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline E. Ridgway more than expected).

Fields of papers citing papers by Caroline E. Ridgway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline E. Ridgway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline E. Ridgway. The network helps show where Caroline E. Ridgway may publish in the future.

Co-authorship network of co-authors of Caroline E. Ridgway

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline E. Ridgway. A scholar is included among the top collaborators of Caroline E. Ridgway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline E. Ridgway. Caroline E. Ridgway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Langley, Paul C., Joseph V. Pergolizzi, Robert Taylor, & Caroline E. Ridgway. (2014). Antioxidant and Associated Capacities of Camu Camu ( Myrciaria dubia ): A Systematic Review. The Journal of Alternative and Complementary Medicine. 21(1). 8–14. 33 indexed citations

2.

Kakuda, Thomas N., Sylvie Abel, John D. Davis, et al.. (2011). Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials. Antimicrobial Agents and Chemotherapy. 55(5). 2290–2296. 29 indexed citations

3.

Abel, Sylvie, et al.. (2008). Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. British Journal of Clinical Pharmacology. 65(s1). 60–67. 81 indexed citations

4.

Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →

5.

Abel, Sylvie, et al.. (2008). The effects of cotrimoxazole or tenofovir co‐administration on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology. 65(s1). 47–53. 17 indexed citations

6.

Abel, Sylvie, et al.. (2008). Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology. 65(s1). 38–46. 65 indexed citations

7.

Pozniak, Anton, Marta Boffito, Deborah Russell, Caroline E. Ridgway, & Gary J. Muirhead. (2008). A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV‐positive subjects. British Journal of Clinical Pharmacology. 65(s1). 54–59. 20 indexed citations

8.

Abel, Sylvie, et al.. (2008). Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/ zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers. British Journal of Clinical Pharmacology. 65(s1). 19–26. 48 indexed citations

9.

Abel, Sylvie, et al.. (2008). Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology. 65(s1). 27–37. 77 indexed citations

10.

Abel, Sylvie, et al.. (2008). Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antiviral Therapy. 14(6). 831–837. 47 indexed citations

11.

Abel, Sylvie, et al.. (2008). Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. British Journal of Clinical Pharmacology. 65(s1). 5–18. 63 indexed citations

12.

Fätkenheuer, Gerd, Anton Pozniak, Margaret Johnson, et al.. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine. 11(11). 1170–1172. 386 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact